Blue Earth Diagnostics, a Bracco company, is highlighting results from a study that explored the impact of urinary activity on the interpretation of its flotufolastat F-18 injection (Posluma).
The company said that results from three blinded readers assessing 712 scans with which the injection was used demonstrated that urinary activity did not influence disease assessment for 96% of the scans. It also said that halo artifacts occurred in just two scans.
Posluma was recently approved by the U.S. Food and Drug Administration and is indicated for PET imaging of prostate-specific membrane antigen-positive lesions in men with prostate cancer.
The study's results were presented June 26 at the Society of Nuclear Medicine and Molecular Imaging annual meeting in Chicago.
